Guggenheim lowered the firm’s price target on Phathom Pharmaceuticals (PHAT) to $18 from $28 and keeps a Buy rating on the shares after having updated the firm’s model to reflect the Q4 report.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHAT:
- Phathom Pharmaceuticals price target lowered to $19 from $27 at Craig-Hallum
- Phathom Pharmaceuticals: Strategic Positioning and Growth Potential in GERD Market Drives Buy Rating
- Phathom Pharmaceuticals Reports Strong Growth with VOQUEZNA
- Phathom Pharmaceuticals: Strong Performance and Optimistic Outlook Amidst Patent Uncertainty
- Phathom Pharmaceuticals reports Q4 EPS ($1.05), consensus ($1.08)